{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:33:48Z","timestamp":1787502828264,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In severe cardiogenic shock the use of temporary mechanical circulatory support has increased during the past decade, with the Impella CP emerging as an alternative to the intra-aortic balloon pump. This study aims to assess the clinical outcomes associated with Impella CP-only support in patients with cardiogenic shock within two tertiary institutions specialised in durable mechanical support in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients receiving Impella CP implantation for cardiogenic shock in the UMC Utrecht and UMC Groningen were studied between December 2020 and August 2023. Exclusion criteria included the use of additional mechanical support. The primary outcome evaluated was 30-day mortality. Secondary outcomes included LVAD implantations, cardiac recovery, and safety outcomes. Patients were categorised as Impella-optimal (Impella support expected to be sufficient) or Impella-limited (Impella support not sufficient but no further escalation because of comorbidities).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted of 28\u00a0patients. The mean age was 60\u00a0years, and 71% were males. In the Impella-limited group, mortality was 100%, and LVAD implantation was performed in just 10%, while in the Impella-optimal group, mortality was 17% and LVAD implantation was performed in 50%. Complications were primarily related to bleeding (7%) and vascular events (11%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study suggests that Impella CP support in cardiogenic shock can be safe and feasible, serving as a\u00a0bridge-to-recovery or a\u00a0bridge-to-decision for LVAD implantation candidacy. However, Impella CP in the Impella-limited group is not useful. This underscores the importance of precise patient selection in cardiogenic shock therapy escalation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-025-01963-2","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:46:31Z","timestamp":1751539591000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Microaxial flow pump in cardiogenic shock: a\u00a0retrospective cohort study on outcomes and feasibility as a\u00a0bridge to LVAD implantation"],"prefix":"10.1007","volume":"33","author":[{"given":"Jan-Willem","family":"Balder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Kraaijeveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"van Laake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Voskuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Droogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Ramjankhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"van de Hoef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannine","family":"Hermens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"van der Harst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Damman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lipsic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabija","family":"Pundziute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"crossref","unstructured":"Zein R, Patel C, Mercado-Alamo A, et\u00a0al. A\u00a0review of the impella devices. Interv Cardiol.17:e5.","DOI":"10.15420\/icr.2021.11"},{"key":"1963_CR2","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne\u00a0RA, Rossello\u00a0X, Coughlan\u00a0JJ, et\u00a0al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the european society of cardiology (ESC). Eur Heart\u00a0J. 2023;44:3720\u2013826.","journal-title":"Eur Heart J"},{"key":"1963_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1161\/CIRCULATIONAHA.118.038201","volume":"139","author":"H Thiele","year":"2019","unstructured":"Thiele\u00a0H, Zeymer\u00a0U, Thelemann\u00a0N, et\u00a0al. Intraaortic balloon pump in cardiogenic shock complicating acute myocardial infarction: Long-term 6\u2011year outcome of the randomized IABP-SHOCK II trial. Circulation. 2019;139:395\u2013403.","journal-title":"Circulation"},{"key":"1963_CR4","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa2312572","volume":"390","author":"JE M\u00f8ller","year":"2024","unstructured":"M\u00f8ller\u00a0JE, Engstr\u00f8m\u00a0T, Jensen\u00a0LO, et\u00a0al. Microaxial flow pump or standard care in infarct-related cardiogenic shock. N\u00a0Engl J Med. 2024;390:1382\u201393.","journal-title":"N Engl J Med"},{"key":"1963_CR5","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/ejhf.3025","volume":"25","author":"M Bogerd","year":"2023","unstructured":"Bogerd\u00a0M, Ten Berg\u00a0S, Peters\u00a0EJ, et\u00a0al. Impella and venoarterial extracorporeal membrane oxygenation in cardiogenic shock complicating acute myocardial infarction. Eur J Heart Fail. 2023;25:2021\u201331.","journal-title":"Eur J Heart Fail"},{"key":"1963_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijcard.2020.09.044","volume":"324","author":"M Iannaccone","year":"2021","unstructured":"Iannaccone\u00a0M, Albani\u00a0S, Giannini\u00a0F, et\u00a0al. Short term outcomes of impella in cardiogenic shock: a\u00a0review and meta-analysis of observational studies. Int J Cardiol. 2021;324:44\u201351.","journal-title":"Int J Cardiol"},{"key":"1963_CR7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCULATIONAHA.121.058229","volume":"145","author":"E L\u00fcsebrink","year":"2022","unstructured":"L\u00fcsebrink\u00a0E, Kellnar\u00a0A, Krieg\u00a0K, et\u00a0al. Percutaneous transvalvular microaxial flow pump support in cardiology. Circulation. 2022;145:1254\u201384.","journal-title":"Circulation"},{"key":"1963_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s12471-024-01872-w","volume":"32","author":"J Balder","year":"2024","unstructured":"Balder\u00a0J, Szymanski\u00a0MK, van Laake\u00a0LW, et\u00a0al. ECPELLA as a\u00a0bridge-to-decision in refractory cardiogenic shock: a\u00a0single-centre experience. Neth Heart\u00a0J. 2024;32:245\u201353.","journal-title":"Neth Heart J"},{"key":"1963_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jacc.2022.01.018","volume":"79","author":"SS Naidu","year":"2022","unstructured":"Naidu\u00a0SS, Baran\u00a0DA, Jentzer\u00a0JC, et\u00a0al. SCAI SHOCK stage classification expert consensus update: a\u00a0review and incorporation of validation studies: this statement was endorsed by the american college of cardiology (ACC), american college of emergency physicians (ACEP), american heart association (AHA), european society of cardiology (ESC) association for acute cardiovascular care (ACVC), international society for heart and lung transplantation (ISHLT), society of critical care medicine (SCCM), and society of thoracic surgeons (STS). J\u00a0Am Coll Cardiol. 2022;79:933\u201346.","journal-title":"J Am Coll Cardiol"},{"key":"1963_CR10","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1161\/CIRCULATIONAHA.120.048792","volume":"142","author":"B Schrage","year":"2020","unstructured":"Schrage\u00a0B, Becher\u00a0PM, Bernhardt\u00a0A, et\u00a0al. Left ventricular unloading is associated with lower mortality in patients with cardiogenic shock treated with venoarterial extracorporeal membrane oxygenation: Results from an international, multicenter cohort study. Circulation. 2020;142:2095\u2013106.","journal-title":"Circulation"},{"key":"1963_CR11","first-page":"101007","volume":"25","author":"G Panuccio","year":"2022","unstructured":"Panuccio\u00a0G, Neri\u00a0G, Macr\u00ec\u00a0LM, et\u00a0al. Use of impella device in cardiogenic shock and its clinical outcomes: a\u00a0systematic review and meta-analysis. Int J Cardiol Heart Vasc. 2022;25:101007.","journal-title":"Int J Cardiol Heart Vasc"},{"key":"1963_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jacc.2016.10.022","volume":"69","author":"DM Ouweneel","year":"2017","unstructured":"Ouweneel\u00a0DM, Eriksen\u00a0E, Sjauw\u00a0KD, et\u00a0al. Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after Acute Myocardial infarction. J\u00a0Am Coll Cardiol. 2017;69:278\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"1963_CR13","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/HCO.0000000000000967","volume":"37","author":"SB Brusca","year":"2022","unstructured":"Brusca\u00a0SB, Caughron\u00a0H, Njoroge\u00a0JN, et\u00a0al. The shock team: a\u00a0multidisciplinary approach to early patient phenotyping and appropriate care escalation in cardiogenic shock. Curr Opin Cardiol. 2022;37:241\u20139.","journal-title":"Curr Opin Cardiol"},{"key":"1963_CR14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2022.08.807","volume":"80","author":"M Pahuja","year":"2022","unstructured":"Pahuja\u00a0M, Johnson\u00a0A, Kabir\u00a0R, et\u00a0al. Randomized trials of percutaneous microaxial flow pump devices: JACC state-of-the-art review. J\u00a0Am Coll Cardiol. 2022;80:2028\u201349.","journal-title":"J Am Coll Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-01963-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01963-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:49:16Z","timestamp":1757206156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-01963-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":14,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-01963-2","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"28 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.\u00a0Kraaijeveld has received speaker fees from Abiomed. Outside the scope of this work, he has received speaker fees from Inari, consultancy fees from Boston Scientific and Pulsecath, and an institutional research grant from Xenios AG. These fees were paid to the University Medical Center Utrecht. L.\u00a0van Laake has received consultancy fees from Abbott, Medtronic, Vifor and Novartis, which were paid to the University Medical Centre Utrecht. L.\u00a0van Laake, M.\u00a0Voskuil and T.\u00a0van de Hoef are associate editors of the Netherlands Heart Journal. T.\u00a0van de Hoef received Institutional research grant from Philips. P.\u00a0van der Harst is editor-in-chief of the Netherlands Heart Journal. K.\u00a0Damman received speaker\/consultancy fees from Abbott, Boehringer Ingelheim, FIRE1, Novartis, Astrazeneca, Echosense, Corteria. These fees were paid to the University Medical Center Groningen. E.\u00a0Lipsic receiver Institutional Educational Grant from Abbott Medical. J.-W.\u00a0Balder, M.\u00a0Szymanski, E.\u00a0Hart, J.\u00a0Droogh, F.\u00a0Ramjankhan, J.\u00a0Hermens, G.\u00a0Pundziute and M.\u00a0Dickinson declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}